Tom P. Monie
University of Cambridge
57 Papers
186 Citations
Tom P. Monie is an academic researcher from University of Cambridge. The author has contributed to research in topics: Biology & Signal transduction. The author has an hindex of 23, co-authored 53 publications. Previous affiliations of Tom P. Monie include Medical Research Council & Imperial College London.
Chat about Author
Papers
Inflammasome activation causes dual recruitment of NLRC4 and NLRP3 to the same macromolecular complex
Si Ming Man,Lee Hopkins,Eileen Nugent,Susan Cox,Ivo M. Glück,Panagiotis Tourlomousis,John A. Wright,Pietro Cicuta,Tom P. Monie,Clare E. Bryant +9 more
TL;DR: The data reveal the spatial localization of different components of the inflammasome and how different members of the NLR family cooperate to drive robust IL-1β processing within the Salmonella-infected cell and to regulate the bacterial burden in mice.
Pathogen sensing by nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide and ATP.
Jinyao Mo,Joseph P. Boyle,Christopher B. Howard,Tom P. Monie,Beckley K. Davis,Joseph A. Duncan +5 more
TL;DR: In this article, the authors demonstrate that NOD2 is able to bind and hydrolyzes ATP and can associate with known NOD-interacting proteins in vitro, and they also demonstrate that the purified recombinant protein can bind directly to muramyl dipeptide.
167
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors
Stephen P.H. Alexander,Doriano Fabbro,Eamonn Kelly,Alistair Mathie,John A. Peters,Emma L. Veale,Jane F. Armstrong,Elena Faccenda,Simon D. Harding,Adam J. Pawson,Christopher Southan,Jamie A. Davies,Annie Beuve,Peter Brouckaert,Clare E. Bryant,John C. Burnett,Richard W. Farndale,Andreas Friebe,John Garthwaite,Adrian J. Hobbs,Gavin E. Jarvis,Michaela Kuhn,David J. MacEwan,Tom P. Monie,Andreas Papapetropoulos,Lincoln R. Potter,Harald H.H.W. Schmidt,Csaba Szabó,Scott A. Waldman +28 more
TL;DR: The Concise Guide to PHARMACOLOGY 2021/22 as mentioned in this paper provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands.
Viral Inhibitory Peptide of TLR4, a Peptide Derived from Vaccinia Protein A46, Specifically Inhibits TLR4 by Directly Targeting MyD88 Adaptor-Like and TRIF-Related Adaptor Molecule
Tatyana Lysakova-Devine,B. Keogh,Barry Harrington,Kamalpreet Nagpal,Annett Halle,Douglas T. Golenbock,Tom P. Monie,Andrew G. Bowie +7 more
TL;DR: Overall, this work demonstrates for the first time disruption of a specific TLR signaling pathway by a short virally derived peptide from A46, which, when fused to a cell-penetrating delivery sequence, potently inhibits TLR4-mediated responses.
Elucidation of the MD-2/TLR4 Interface Required for Signaling by Lipid IVa
Catherine M. Walsh,Monique Gangloff,Tom P. Monie,Tomoko Smyth,Bin Wei,Trevelyan J. McKinley,Duncan J. Maskell,Clare E. Bryant +7 more
TL;DR: A mechanism of signaling that involves crosslinking mediated by both MD-2-receptor and receptor-re receptor contacts in a model that shows striking similarities to the recently published structure of the ligand-bound TLR1/2 ectodomain heterodimer is suggested.
127